Amgen Patent Suit Targets Sandoz's Enbrel Biosimilar
Amgen launched a patent suit against Sandoz on Friday in New Jersey federal court to delay a biosimilar version of its blockbuster immunosuppressant Enbrel, teeing up a fight with multibillion-dollar stakes....To view the full article, register now.
Already a subscriber? Click here to view full article